Sanofi Reports Q1 Growth Driven by Dupixent Surge; Maintains 2026 Outlook

Sanofi (SNY) reported a strong start to the 2026 fiscal year, highlighted by a significant increase in net sales and business earnings per share. The company's growth was primarily propelled by its blockbuster drug Dupixent and a series of strategic acquisitions and product launches. First quarter net sales reached 10.51 billion euros, up from 9.89 billion euros in the prior year, representing a 6.2% increase at actual exchange rates. Dupixent sales were a standout performer, climbing 30.8% to reach 4.2 billion euros. While net income from continuing operations declined to 1.59 billion euros from 1.72 billion euros, core business metrics remained positive. Business net income rose to 2.26 billion euros, and business earnings per share increased to 1.88 euros from 1.79 euros. Interim CEO Olivier Charmeil noted that sales grew by 13.6% when adjusted, citing the success of recent pharma launches as a primary driver. Looking ahead, Sanofi has reiterated its guidance for 2026. The company continues to expect sales to grow by a high single-digit percentage, with business EPS expected to grow slightly faster than sales at constant exchange rates. Following the report, shares were trading at 80.78 euros, reflecting a marginal decline of 0.30%.